Elkedonia strengthens Board of Directors with appointment of Pierre d’Epenoux as Independent ChairmanStrasbourg, France and Charleroi, Belgium, 22 April 2026 (0830 CET) – Elkedonia, a biotech company pioneering a novel neuroplastogen approach to develop therapeutics for severe depression and other neuropsychiatric conditions, today announces the appointment of pharmaceutical and biotech executive Pierre d’Epenoux as Independent Chairman to its Board of Directors.
Elkedonia closes EUR 11 million seed round to advance neuroplastogens as novel therapeutics for depression and neuropsychiatric disordersStrasbourg, France and Charleroi, Belgium, June 11th 2025 – Elkedonia SAS, a company pioneering a novel neuroplastogen approach to develop therapeutic agents to treat depression and other neuropsychiatric condition, announced today that it has closed an oversubscribed EUR 11.25 million Seed funding round. The round was co-led by Kurma Partners, WE Life Sciences and the French Tech Seed fund managed on behalf of the French government by Bpifrance as part of France 2030, with participation from Argobio, Angelini Ventures, CARMA Fund, Capital Grand Est and Sambrinvest. Elkedonia is bringing together stakeholders from across the European ecosystem, with headquarters in Strasbourg, France and an affiliate in Charleroi, Belgium.
